Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 10/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27487738 | 1.00 | OPRK1 (0.56) | OPRK1OPRD1ATMOPRM1ALDH1A1 | |
| SCHEMBL6326395 | 0.83 | ATM (0.59) | OPRK1OPRD1ATMOPRM1ANPEP | |
| SCHEMBL271176 | 0.81 | ATM (0.51) | OPRK1OPRD1ATMOPRM1ALDH1A1 | |
| SCHEMBL27488811 | 0.79 | ALDH1A1 (0.45) | OPRK1OPRD1OPRM1ALDH1A1LMNA | |
| SCHEMBL7065014 | 0.79 | ALDH1A1 (0.45) | OPRK1OPRD1OPRM1ALDH1A1LMNA | |
| SCHEMBL6318927 | 0.79 | HPGD (0.50) | OPRK1OPRD1OPRM1ALDH1A1HPGD | |
| SCHEMBL19385457 | 0.79 | HPGD (0.50) | OPRK1OPRD1OPRM1ALDH1A1HPGD | |
| SCHEMBL25152807 | 0.78 | OPRK1 (0.57) | OPRK1OPRD1ATMOPRM1ALDH1A1 | |
| SCHEMBL7064800 | 0.78 | HPGD (0.49) | OPRK1OPRD1OPRM1HPGD | |
| SCHEMBL19385528 | 0.78 | HPGD (0.49) | OPRK1OPRD1OPRM1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
| CN-1211991-A | Compounds with growth hormone releasing properties | NOVO NORDISK AS (DK) | 1999-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | OPRK1 552/4885OPRD1 484/4885ATM 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.